TR201900659T4 - Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. - Google Patents
Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. Download PDFInfo
- Publication number
- TR201900659T4 TR201900659T4 TR2019/00659T TR201900659T TR201900659T4 TR 201900659 T4 TR201900659 T4 TR 201900659T4 TR 2019/00659 T TR2019/00659 T TR 2019/00659T TR 201900659 T TR201900659 T TR 201900659T TR 201900659 T4 TR201900659 T4 TR 201900659T4
- Authority
- TR
- Turkey
- Prior art keywords
- compound
- formula
- mixture
- added
- benzoxazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018790P | 2014-06-30 | 2014-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201900659T4 true TR201900659T4 (tr) | 2019-02-21 |
Family
ID=53539739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/00659T TR201900659T4 (tr) | 2014-06-30 | 2015-06-26 | Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10017502B2 (enExample) |
| EP (1) | EP3160948B1 (enExample) |
| JP (1) | JP6368383B2 (enExample) |
| KR (1) | KR102012222B1 (enExample) |
| CN (1) | CN106536491B (enExample) |
| AR (1) | AR101036A1 (enExample) |
| AU (1) | AU2015282450C1 (enExample) |
| CA (1) | CA2953655C (enExample) |
| CY (1) | CY1121596T1 (enExample) |
| DK (1) | DK3160948T3 (enExample) |
| EA (1) | EA029518B1 (enExample) |
| ES (1) | ES2707726T3 (enExample) |
| HR (1) | HRP20190147T1 (enExample) |
| HU (1) | HUE042370T2 (enExample) |
| LT (1) | LT3160948T (enExample) |
| ME (1) | ME03316B (enExample) |
| MX (1) | MX367404B (enExample) |
| PL (1) | PL3160948T3 (enExample) |
| PT (1) | PT3160948T (enExample) |
| RS (1) | RS58274B1 (enExample) |
| SI (1) | SI3160948T1 (enExample) |
| SM (1) | SMT201900039T1 (enExample) |
| TR (1) | TR201900659T4 (enExample) |
| TW (1) | TWI677498B (enExample) |
| UY (1) | UY36195A (enExample) |
| WO (1) | WO2016001631A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201900659T4 (tr) * | 2014-06-30 | 2019-02-21 | Astrazeneca Ab | Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. |
| MY210508A (en) | 2018-07-19 | 2025-09-28 | Astrazeneca Ab | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
| CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
| PE20211267A1 (es) * | 2019-08-30 | 2021-07-19 | Astrazeneca Ab | Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina |
| EP4188389B1 (en) | 2020-07-27 | 2025-09-17 | AstraZeneca AB | Dapagliflozin for use in methods of treating chronic kidney disease |
| US12409186B2 (en) | 2020-07-27 | 2025-09-09 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| EP4357336A4 (en) * | 2021-06-15 | 2025-07-02 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | BENZOXAZINONE DERIVATIVES |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| JP2025527854A (ja) | 2022-09-01 | 2025-08-22 | アストラゼネカ・アクチエボラーグ | 心腎疾患の治療に使用するためのｓｇｌｔ２阻害剤と鉱質コルチコイド受容体調節剤との組み合わせ |
| CN120344508A (zh) * | 2022-12-15 | 2025-07-18 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类化合物的结晶及其制备 |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6951855B2 (en) * | 2001-04-23 | 2005-10-04 | Astrazeneca Ab | Benzoxazinone derivatives for use in the treatment of angiogenesis |
| BR0317572A (pt) * | 2002-12-20 | 2005-11-22 | Warner Lambert Co | Benzoxazinas e seus derivados como inibidores de pi3ks |
| WO2006019716A1 (en) * | 2004-07-14 | 2006-02-23 | Ligand Pharmaceuticals, Inc. | Intracellular receptor modulator compounds and methods |
| BRPI0512674A (pt) * | 2004-07-28 | 2007-09-25 | Irm Llc | compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide |
| WO2007077961A2 (en) | 2005-12-28 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| BRPI0717937A2 (pt) | 2006-10-31 | 2013-12-03 | Pfizer Prod Inc | Compostos de pirazona como antagonistas do receptor mineralocorticóide |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| WO2008118319A2 (en) | 2007-03-23 | 2008-10-02 | Merck & Co., Inc. | Mineralocorticoid receptor modulators |
| DK2133330T3 (da) | 2007-04-09 | 2014-03-31 | Daiichi Sankyo Co Ltd | Atropisomer af pyrrolderivat |
| US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
| KR20110017456A (ko) * | 2008-06-18 | 2011-02-21 | 아스트라제네카 아베 | 호흡기 장애의 치료를 위한 베타2-아드레날린성 수용체 효능제로서 작용하는 벤족사지논 유도체 |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
| MX2011009506A (es) | 2009-03-12 | 2011-09-28 | Lilly Co Eli | Antagonista del receptor mineralcorticoide y metodos de uso. |
| US20120022058A1 (en) | 2009-04-10 | 2012-01-26 | Pfizer Inc. | 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
| CN102906495B (zh) | 2010-05-11 | 2016-08-24 | 皇家飞利浦电子股份有限公司 | 照明模块 |
| CA2798831A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| WO2012064631A1 (en) | 2010-11-10 | 2012-05-18 | Boehringer Ingelheim International Gmbh | Pyridyl ureas as mineralocorticoid receptor antagonists |
| TR201900659T4 (tr) * | 2014-06-30 | 2019-02-21 | Astrazeneca Ab | Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. |
-
2015
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active Active
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/en active
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en not_active Ceased
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 SM SM20190039T patent/SMT201900039T1/it unknown
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201900659T4 (tr) | Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. | |
| CA3133753A1 (en) | Novel small molecule inhibitors of tead transcription factors | |
| EP3204359B1 (en) | Tetrahydroisoquinoline derivatives | |
| CN108727363B (zh) | 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂 | |
| JP2022503942A (ja) | イソインドリン化合物、その調製方法、医薬組成物および使用 | |
| CA2737038A1 (en) | Amide compounds, compositions and uses thereof | |
| CA3203285A1 (en) | Heteroaryl carboxamide compound | |
| KR20240073108A (ko) | Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄 | |
| CA3085879A1 (en) | Substituted pyrrolidine amides ii | |
| CA3234429A1 (en) | Ras inhibitors, compositions and methods of use thereof | |
| ES2923138T3 (es) | Procedimiento para preparar un intermedio del fármaco antitumoral niraparib e intermedio del mismo | |
| Pan et al. | Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors | |
| WO2024246496A1 (en) | (hetero)aryl-carbonyl-heterobicyclic compounds as inhibitors of pms2 for cancer and degenerative illnesses | |
| CA2985021A1 (en) | Selective modulators of the activity of the gpr55 receptor: chromenopyrazole derivatives | |
| CN116969888A (zh) | 含环丙基并环类衍生物、其药学上可接受的盐及其制备方法和应用 | |
| CN121152792A (zh) | 具有Nrf2活化作用的含氮杂环化合物的晶体 | |
| HK1237338A1 (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| HK1237338B (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| JP2016108326A (ja) | 環状アミノメチルピリミジン誘導体からなる医薬 | |
| KR20090034787A (ko) | 모르피난 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |